News
ADCT
1.150
-5.74%
-0.070
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why
Benzinga · 4d ago
ADC Therapeutics Halts LOTIS-10 Liver-Impairment Study: What It Means for Zynlonta and Investors
TipRanks · 5d ago
Weekly Report: what happened at ADCT last week (0713-0717)?
Weekly Report · 5d ago
Weekly Report: what happened at ADCT last week (0706-0710)?
Weekly Report · 07/13 09:56
Weekly Report: what happened at ADCT last week (0629-0703)?
Weekly Report · 07/06 09:59
ADC Therapeutics Grants One-Time Retention Awards to Executives
TipRanks · 07/02 21:30
ADC Therapeutics Announces New Employee Inducement Grant
PR Newswire · 07/01 20:05
Analysts Are Bullish on Top Healthcare Stocks: ADC Therapeutics (ADCT), Moleculin Biotech (MBRX)
TipRanks · 07/01 18:20
ADC Therapeutics completes enrollment in Phase 1b Zynlonta trial
TipRanks · 06/30 11:20
ADC Therapeutics Completes Enrollment In LOTIS-7 Phase 1b Open-Label Clinical Trial Evaluating ZYNLONTA In Combination With Bispecific Antibody Glofitamab In Patients With R/R Diffuse Large B-Cell Lymphoma
Benzinga · 06/30 11:19
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
PR Newswire · 06/30 11:15
Weekly Report: what happened at ADCT last week (0622-0626)?
Weekly Report · 06/29 09:55
Analysts Offer Insights on Healthcare Companies: ADC Therapeutics (ADCT) and Lantheus (LNTH)
TipRanks · 06/27 13:30
Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired
NASDAQ · 06/26 14:33
ADC Therapeutics Cuts Workforce To Advance ZYNLONTA Portfolio In B-Cell Lymphoma
NASDAQ · 06/25 06:15
ADC Therapeutics Announces ZYNLONTA-Focused Strategic Reorganization
TipRanks · 06/24 13:29
ADC Therapeutics to reduce workforce by 17% globally
TipRanks · 06/24 11:35
ADC Therapeutics Announces Strategic Reorganization To Focus Resources Behind Key Value-Driving Initiatives In Support Of ZYNLONTA Franchise
Benzinga · 06/24 11:33
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
PR Newswire · 06/24 11:30
Tango Appoints Robert Azelby To Board Of Directors
NASDAQ · 06/23 10:03
More
Webull provides a variety of real-time ADCT stock news. You can receive the latest news about Adc Therapeutics Sa through multiple platforms. This information may help you make smarter investment decisions.
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.